Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target
Benzinga Newsdesk 4 days ago
Analyst RatingsNewsReiterationPrice Target
Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $200 price target.
Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $200 price target.